What is Rhinomed?
Rhinomed operates at the intersection of medical device engineering and consumer health, focusing on the development of wearable nasal technology designed to optimize respiration. By addressing critical needs in sleep quality, athletic performance, and diagnostic efficiency, the company has carved out a unique niche. Its product portfolio, which includes the Mute and Turbine devices, leverages mechanical airflow enhancement to improve user outcomes. Furthermore, the introduction of the Rhinoswab represents a significant advancement in diagnostic standardization, particularly for pediatric applications, positioning the company as a key player in the global respiratory health market.
How much funding has Rhinomed raised?
Rhinomed has raised a total of $6M across 1 funding round:
Stock/Share Issuance
$6M
Stock/Share Issuance (2025): $6M, investors not publicly disclosed
Key Investors in Rhinomed
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Rhinomed?
With this major enterprise-level funding, Rhinomed is poised to scale its operational capabilities and expand its global distribution footprint. The strategic allocation of this capital will likely prioritize the commercialization of its diagnostic pipeline and the enhancement of its manufacturing processes to meet rising demand. As the company transitions into this next phase of growth, the focus will remain on clinical validation and the integration of its nasal technology into broader healthcare ecosystems, ensuring that Rhinomed remains at the forefront of respiratory innovation and patient-centric care solutions.
See full Rhinomed company page
